Fig. 2

Fig. 2

Compound B reduces ovarian cancer metastasis comparably to cisplatin.Images show ovarian cancer cells labeled with DiI membrane stain visible in the red fluorescent channel. A.-D. Representative images of microinjected zebrafish embryos (A. brightfield cranial view showing yolk sac injection site (black arrow); B. brightfield caudal view; C. red channel fluorescent cranial view showing yolk sac injection site with cancer cells (white arrow); D. red channel fluorescent caudal view showing metastasized A2780cis cells (white arrow head), E.-J. Representative images of control and experimental treatment zebrafish (E., E3 media control; F., 0.9% NaCl cisplatin control; G., 0.3% DMSO compound B control; H., 0.3 µM compound B; I., 0.6 µM compound B; J., 2.0 µM cisplatin). K. Comparison of E3 media (Con), 0.9% NaCl, and 0.3% DMSO controls. L. Comparison of E3 control (Con) with three platinum complex treatments: 0.3 µM compound B [B(0.3)], 0.6 µM compound B [B(0.6)], 2.0 µM cisplatin [C(2.0)]. CTCF = corrected total cell fluorescence; p < 0.05, “*” = 0.05; N = 5–15